Snap Circuits Extreme SC-750 Electronics Discovery Kit

This Snap Circuits Extreme Electronics kit lets you create your own experiments and build over 750 exciting projects. Contains more than 80 pieces. Parts are color-coded and projects go together with ease. The Snap Circuits Extreme Electronics Kit makes learning about electronics fun.

Product Features

  • Build over 750 experiments with 80 parts
  • Experiments included: sound activated switch, lie detector, adjustable light controller, am radio, rechargeable battery and many more. Use your Windows PC and the included CI-73 Computer Interface manual converts your computer monitor into an oscilloscope and lets you see signals in process in the circuits you assemble
  • Parts included: photoresist or, power amplifier, variable capacitor, analog meter, solar cell, computer interface, full color manuals
  • Snap-Circuits have received the following Awards: National Parenting Center-Seal of Approval, Creative Child ?Toy of the Year
  • Toy Industry Association – Specialty Toy of the Year, Dr. Toy 100 Best Children’s Products, Dr. Toy 10 Best Educational Products

Detailed information available on our homepage…

Information Medicine: The Revolutionary Cell-Reprogramming Discovery that Reverses Cancer and Degenerative Diseases

A look at the future of medicine based on cutting-edge stem cell research

• Shares Dr. Biava’s groundbreaking research on stem cell differentiation stage factors (SCDSFs) as a cellular “reprogramming” treatment for cancer and other degenerative diseases such as psoriasis and Parkinson’s

• Explains how SCDSFs restore communication between cells and the epigenetic code, the information that programs the normal function and growth of every living cell

• Explores how the universe operates like a cosmic information-network and how this new scientific worldview will shape the future of healing and medicine

The universe is not a mechanical system of matter–it operates like a cosmic network that runs on and is connected by information. Information “in-forms” and underlies all of the physical world, including the human body. In this book, Pier Mario Biava, M.D., and Ervin Laszlo, Ph.D., show how this “information” worldview can be applied to healing and medicine and, specifically, how it underlies a revolutionary new approach to cancer and disease treatment, one that works directly with the epigenetic code–the information that programs the function and growth of every living cell.

The authors explain how tumor growth and cellular dysfunction are manifestations of disconnections in the information network of an organism. Unveiling Dr. Biava’s groundbreaking research on stem cell differentiation stage factors (SCDSFs), they explain how SCDSFs work directly with the epigenetic code to reconnect aberrant cells to the body’s information network and reset them to their original function–in the case of cancer cells transforming them from malignant to benign, from dysfunction back to normalcy and health. Dr. Biava’s research on SCDSFs–derived from Zebrafish embryos, which have 95 percent the same proteins as humans–has shown great success in reprogramming and inhibiting cancer cells in clinical trials with patients with advanced liver cancer, as well as success in in vitro studies with 7 different human tumor lines. SCDSFs have also shown promise in the treatment of chronic diseases such as psoriasis and neurodegenerative conditions, including Parkinson’s and Alzheimer’s.

Unveiling the holistic future of medicine, the authors show how we will no longer need to approach the treatment of cancer and other degenerative diseases as a “fight,” but as a restoration of our cells’ original programming. With the advent of Information Medicine, we now have the power to program ourselves to heal.

Detailed information available on our homepage…

Stem Cells and Cancer (Cancer Drug Discovery and Development)

Significance of Stem Cells to Tumor Development

Cancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve. A recent surge in stem cell research has ignited a field of discovery into many human diseases including diabetes, neuropathologies, and cancer. By replacing specific differentiated cells that have either been lost or died, stem cell therapy proves to be a very promising approach to the treatment of many debilitating diseases. Though stem cells may provide therapeutic benefit under certain conditions, they are also often implicated in the initiation, progression, and therapeutic resistance of malignant disease.

This first edition of Stem Cells and Cancer is intended to give a current perspective on the role of stem cells in cancer and strategies for novel therapies directed toward tumor stem cells. The current cancer stem cell hypothesis is presented in several chapters with distinctions made between the hierarchical and stochastic models of tumor cell development. “Stemness,” self-renewal, pluripotency, clonality, and tumorigenicity are important concepts applied towards defining cancer stem cells. Signaling pathways such as Wnt, Sonic Hedgehog, Notch, and Bmi-1 that are involved in differentiation, proliferation, and survival are implicated in the malignant process. Additional chapters address the identification of cancer stem cell populations through the evaluation of molecular markers such as CD133, CD44, and CD24, for example, or by Hoescht dye exclusion to recognize ‘side populations.’ Mesenchymal and hematopoietic stem cells are described as well as mouse models that are employed to elucidate the properties and functionality of stem cells in cancer and the stem cell niche. This book encompasses a wide variety of human cancers that include but are not limited to leukemia, gliomas, breast, and prostate cancers. Resistance to conventional therapies, genetic versus epigenetic changes that affect therapeutic response and strategies to prevent disease recurrence are challenges have been incorporated into this volume. Stem Cells and Cancer represents a compendium of cutting edge research by experts in the field and will be instrumental in the study of this intriguing line of investigation for many years to come.

Rebecca Bagley is a senior scientist at Genzyme Corporation and has worked in the biotechnology industry for 20 years with degrees in biology from Wellesley College and Harvard University. Her expertise in drug development spans a wide range of approaches including immunotherapies,  gene and protein therapies, and small molecule delivery with publications in journals such as Molecular Cancer Therapeutics, Cancer Research, and Microvascular Research . Her current research focuses on stem cells, tumor vasculature, and target validation.

Dr. Beverly A. Teicher is Vice President of Oncology Research at Genzyme Corporation. Dr. Teicher completed a PhD in Bioorganic Chemistry at the Johns Hopkins University and postdoctoral training at Yale University School of Medicine. Dr. Teicher joined Dana-Farber Cancer Institute as an Assistant Professor of Pathology and rose to Associate Professor of Medicine and Radiation Therapy, Harvard Medical School at Dana-Farber Cancer Institute and Joint Center for Radiation Therapy. Dr. Teicher is an active member of the international scientific community having authored or co-authored more than 400 scientific publications. She has edited eight books, is senior editor for the journal Clinical Cancer Research and is series editor for the Cancer Drug Discovery and Development book series.

Visit the website for more information…